177 related articles for article (PubMed ID: 23589147)
1. The effect of rifaximin on gut flora and Staphylococcus resistance.
Kim MS; Morales W; Hani AA; Kim S; Kim G; Weitsman S; Chang C; Pimentel M
Dig Dis Sci; 2013 Jun; 58(6):1676-82. PubMed ID: 23589147
[TBL] [Abstract][Full Text] [Related]
2. Rifaximin intake leads to emergence of rifampin-resistant staphylococci.
Valentin T; Leitner E; Rohn A; Zollner-Schwetz I; Hoenigl M; Salzer HJ; Krause R
J Infect; 2011 Jan; 62(1):34-8. PubMed ID: 21073894
[TBL] [Abstract][Full Text] [Related]
3. Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations.
Debbia EA; Maioli E; Roveta S; Marchese A
J Chemother; 2008 Apr; 20(2):186-94. PubMed ID: 18467244
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of rifaximin against isolates from patients with small intestinal bacterial overgrowth.
Pistiki A; Galani I; Pyleris E; Barbatzas C; Pimentel M; Giamarellos-Bourboulis EJ
Int J Antimicrob Agents; 2014 Mar; 43(3):236-41. PubMed ID: 24461710
[TBL] [Abstract][Full Text] [Related]
5. Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci.
DuPont HL; Jiang ZD
Clin Microbiol Infect; 2004 Nov; 10(11):1009-11. PubMed ID: 15522005
[TBL] [Abstract][Full Text] [Related]
6. Rifamycin resistance, rpoB gene mutation and clinical outcomes of Staphylococcus species isolates from prosthetic joint infections in Republic of Korea.
Lee Y; Kim SS; Choi SM; Bae CJ; Oh TH; Kim SE; Kim UJ; Kang SJ; Jung SI; Park KH
J Glob Antimicrob Resist; 2022 Mar; 28():43-48. PubMed ID: 34920175
[TBL] [Abstract][Full Text] [Related]
7. Emergence of rifampin-resistant staphylococci after rifaximin administration in cirrhotic patients.
Chang JY; Kim SE; Kim TH; Woo SY; Ryu MS; Joo YH; Lee KE; Lee J; Lee KH; Moon CM; Jung HK; Shim KN; Jung SA
PLoS One; 2017; 12(10):e0186120. PubMed ID: 28982166
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of rifaximin against clinical isolates of Escherichia coli and other enteropathogenic bacteria isolated from travellers returning to the UK.
Hopkins KL; Mushtaq S; Richardson JF; Doumith M; de Pinna E; Cheasty T; Wain J; Livermore DM; Woodford N
Int J Antimicrob Agents; 2014 May; 43(5):431-7. PubMed ID: 24661532
[TBL] [Abstract][Full Text] [Related]
9. Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity.
Pimentel M; Cash BD; Lembo A; Wolf RA; Israel RJ; Schoenfeld P
Dig Dis Sci; 2017 Sep; 62(9):2455-2463. PubMed ID: 28589238
[TBL] [Abstract][Full Text] [Related]
10. Antibiotic prophylaxis prevents the development of a post-infectious phenotype in a new rat model of post-infectious IBS.
Pimentel M; Morales W; Jee SR; Low K; Hwang L; Pokkunuri V; Mirocha J; Conklin J; Chang C
Dig Dis Sci; 2011 Jul; 56(7):1962-6. PubMed ID: 21222158
[TBL] [Abstract][Full Text] [Related]
11. Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile.
O'Connor JR; Galang MA; Sambol SP; Hecht DW; Vedantam G; Gerding DN; Johnson S
Antimicrob Agents Chemother; 2008 Aug; 52(8):2813-7. PubMed ID: 18559647
[TBL] [Abstract][Full Text] [Related]
12. Rifaximin: An Antibiotic with Important Biologic Effects.
DuPont HL
Mini Rev Med Chem; 2015; 16(3):200-5. PubMed ID: 26202192
[TBL] [Abstract][Full Text] [Related]
13. Rifampin Resistance in Staphylococci after Rifaximin Intake for Surgical Prophylaxis in Elective Colorectal Surgery.
Padilla E; Oms L; Espejo E; Gómez L; Pagespetit L; Boada N; Bella F; Pérez J
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249689
[TBL] [Abstract][Full Text] [Related]
14. Rifaximin disc diffusion test for in vitro susceptibility testing of Clostridium difficile.
Huhulescu S; Sagel U; Fiedler A; Pecavar V; Blaschitz M; Wewalka G; Allerberger F; Indra A
J Med Microbiol; 2011 Aug; 60(Pt 8):1206-1212. PubMed ID: 21292853
[TBL] [Abstract][Full Text] [Related]
15. In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas.
Jiang ZD; DuPont HL; La Rocco M; Garey KW
J Clin Pathol; 2010 Apr; 63(4):355-8. PubMed ID: 20354207
[TBL] [Abstract][Full Text] [Related]
16. Bacteraemia with rifampin-resistant Staphylococcus aureus and the potential role of cross-resistance between rifampin and rifaximin.
Valentin T; Hoenigl M; Wagner J; Krause R; Zollner-Schwetz I
J Infect; 2014 Sep; 69(3):295-7. PubMed ID: 24780764
[No Abstract] [Full Text] [Related]
17. Sensitivity to rifaximin and rifampicin of Mycobacterium tuberculosis isolated from guinea pigs treated orally with rifaximin.
Malvisi Stracciari J; Venturini AP; Anfossi P; Marchi E; Stracciari GL
Chemioterapia; 1987 Apr; 6(2):82-4. PubMed ID: 3109750
[TBL] [Abstract][Full Text] [Related]
18. Rifaximin-resistant Clostridium difficile strains isolated from symptomatic patients.
Reigadas E; Muñoz-Pacheco P; Vázquez-Cuesta S; Alcalá L; Marín M; Martin A; Bouza E
Anaerobe; 2017 Dec; 48():269-272. PubMed ID: 28988773
[TBL] [Abstract][Full Text] [Related]
19. Effects of daily oral administration of rifaximin and neomycin on faecal aerobic flora in rats.
Miglioli PA; Allerberger F; Calabrò GB; Gaion RM
Pharmacol Res; 2001 Nov; 44(5):373-5. PubMed ID: 11712867
[TBL] [Abstract][Full Text] [Related]
20. Rifamycins, Alone and in Combination.
Rothstein DM
Cold Spring Harb Perspect Med; 2016 Jul; 6(7):. PubMed ID: 27270559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
